U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[_] Check box if no longer subject of Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
________________________________________________________________________________
1. Name and Address of Reporting Person*
J.P. Morgan Partners (SBIC), LLC
(f/k/a/Chase Venture Capital Associates, LLC)
--------------------------------------------------------------------------------
(Last) (First) (Middle)
c/o J.P. Morgan Partners, LLC
1221 Avenue of the Americas-40th Floor
--------------------------------------------------------------------------------
(Street)
New York New York 10020
--------------------------------------------------------------------------------
(City) (State) (Zip)
________________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
Praecis Pharmaceuticals Incorporated ("PRCS")
________________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
________________________________________________________________________________
4. Statement for Month/Year
December 2000
________________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
================================================================================
6. Relationship of Reporting Person to Issuer
(Check all applicable)
[_] Director [X] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
________________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form filed by one Reporting Person
[X] Form filed by more than one Reporting Person
________________________________________________________________________________
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ------------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 12/4/00 S 7,500 D $25.06 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/4/00 S 5,000 D $24.99 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/5/00 S 50,000 D $23.99 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/6/00 S 50,000 D $23.99 3,598,704 D
-----------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/6/00 S 50,000 D $24.12 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/6/00 S 30,000 D $24.43 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/6/00 S 10,000 D $24.49 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/6/00 S 5,000 D $24.74 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/7/00 S 25,000 D $24.12 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/7/00 S 5,000 D $24.18 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/8/00 S 50,000 D $23.99 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/8/00 S 15,000 D $24.12 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/8/00 S 10,000 D $24.18 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/11/00 S 20,000 D $23.81 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/11/00 S 10,000 D $23.68 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/11/00 S 85,000 D $23.49 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/12/00 S 10,000 D $23.49 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/12/00 S 10,000 D $23.31 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/13/00 S 65,000 D $22.99 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/19/00 S 280,000 D $22.99 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/19/00 S 50,000 D $23.06 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/19/00 S 150,000 D $23.12 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/18/00 S 57,500 D $22.99 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/26/00 S 100,000 D $25.99 3,598,704 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 12/26/00 S 90,300 D $26.12 3,598,704 D
===================================================================================================================================
</TABLE>
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
(Print or Type Responses)
(Over)
(Form 4-07/99)
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
================================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
or Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
---------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
$7.00
per Common
Options share N/A N/A N/A N/A (FN 1) 1/11/01 Stock 9,166 N/A 9,166 I (FN 1)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Explanation of Responses:
(1) These options were granted to Dr. Damion Wicker, a managing director of
J.P. Morgan Partners (SBIC), LLC ("JPM SBIC"). Dr. Wicker is contractually
obligated to exercise the options at the request of JPM SBIC, and to
transfer any shares issued under the stock options to JPM SBIC. The options
originally had a term of ten years from the date of the grant and vested and
became exercisable in equal monthly installments over a three-year period
provided Dr. Wicker continued to be a member of the Board of Directors of
the Issuer. As of October 13, 2000, Dr. Wicker ceased to be a director of
the Issuer. Options with respect to 9,166 shares had vested as of thatdate;
these options remain exercisable until the 90th day from the date of his
resignation.
J.P. Morgan Partners (SBIC), LLC
/s/ Arnold Chavkin 1/10/01
By: -------------------------------------------- -----------------------
Arnold Chavkin, Date
Managing Director
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
<TABLE>
<CAPTION>
NAME AND ADDRESS OF DESIGNATED STATEMENT ISSUER NAME, TICKER
REPORTING PERSON REPORTER (Note 1 and 2) FOR OR TRADING SYMBOL
MONTH/YEAR
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
J.P. Morgan Partners (BHCA), L.P. J.P. Morgan Partners December, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o J.P. Morgan Partners, LLC (SBIC), LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
JPMP Master Fund Manager, L.P. J.P. Morgan Partners December, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o J.P. Morgan Partners, LLC (SBIC), LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
JPMP Capital Corporation J.P. Morgan Partners December, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o J.P. Morgan Partners, LLC (SBIC), LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
J.P. Morgan Chase & Co. J.P. Morgan Partners December, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o J.P. Morgan Partners, LLC (SBIC), LLC
270 Park Avenue
35th Floor
New York, NY 10017
------------------------------------------------------------------------------------------------------------------------------------
Chatham Ventures, Inc. J.P. Morgan Partners December, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o J.P. Morgan Partners, LLC (SBIC), LLC
1221 Avenue of the Americas
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF TITLE OF AMOUNT OF OWNERSHIP FORM: NATURE OF INDIRECT DISCLAIMS
REPORTING PERSON SECURITY SECURITIES DIRECT (D) OR BENEFICIAL OWNERSHIP PECUNIARY
BENEFICIALLY INDIRECT (I) INTEREST
OWNED
-----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
J.P. Morgan Partners (BHCA), L.P. See Tables I and II See Tables I and II I See Explanatory No
c/o J.P. Morgan Partners, LLC Note 3 below
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
JPMP Master Fund Manager, L.P. See Tables I and II See Tables I and II I See Explanatory No
c/o J.P. Morgan Partners, LLC Note 4 below
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
JPMP Capital Corporation See Tables I and II See Tables I and II I See Explanatory No
c/o J.P. Morgan Partners, LLC Note 5 below
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
J.P. Morgan Chase & Co. See Tables I and II See Tables I and II I See Explanatory No
270 Park Avenue Note 6 below
35th Floor
New York, NY 10017
------------------------------------------------------------------------------------------------------------------------------------
Chatham Ventures, Inc. See Tables I and II See Tables I and II I See Explanatory No
c/o J.P. Morgan Partners, LLC Note 7 below
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
Explanatory Notes:
1) The names of the reporting persons and the Designated Reporter changed
during the first week of January 2001 as a result of internal reorganizations
and name changes effective as of various times during the week. The internal
reorganizations and name changes did not alter the proportionate interests of
the ultimate security holders of the renamed entities.
2) The Designated Reporter is executing this report on behalf of all
Reporting Persons, each of whom has authorized it to do so.
3) The amounts shown in Tables I and II represent the beneficial ownership
of the Issuer's equity securities by JPM SBIC. The Reporting Person is the sole
member of JPM SBIC.
4) The amounts shown in Tables I and II represent the beneficial ownership
of the Issuer's equity securities by JPM SBIC, a portion of which may be deemed
attributable to the Reporting Person because it is the sole general partner of
J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA"), the sole member of JPM SBIC. The
actual pro rata portion of such beneficial ownership that may be deemed to be
attributable to the Reporting Person is not readily determinable because it is
subject to several variables, including the internal rate of return and vesting
of interests within JPM BHCA.
5) The amounts shown in Tables I and II represent the beneficial ownership
of the Issuer's equity securities by JPM SBIC, a portion of which may be deemed
attributable to the Reporting Person because it is the general partner of JPMP
Master Fund Manager, L.P. ("MF Manager"), the general partner of JPM BHCA (the
parent of JPM SBIC). The actual pro rata portion of such beneficial ownership
that may be deemed to be attributable to the Reporting Person is not readily
determinable because it is subject to several variables, including the internal
rate of return and vesting of interests within JPM BHCA and MF Manager.
6) The amounts shown in Tables I and II represent the beneficial ownership
of the Issuer's equity securities by JPM SBIC, a portion of which may be deemed
attributable to the Reporting Person because it is the sole stockholder of JPMP
Capital Corporation (the general partner of MF Manager) and of Chatham Ventures,
Inc., the limited partner of JPM BHCA. The actual pro rata portion of such
beneficial ownership that may be attributable to the Reporting Person is not
readily determinable because it is subject to several variables, including the
internal rate of return and vesting of interests within JPM BHCA and MF Manager.
7) The amounts shown in Tables I and II represent the beneficial ownership
of the Issuer's equity securities by JPM SBIC, a portion of which may be deemed
attributable to the Reporting Person because it is the sole limited partner of
JPM BHCA, the parent of JPM SBIC. The actual pro rata portion of such beneficial
ownership that may be deemed to be attributable to the Reporting Person is not
readily determinable because it is subject to several variables, including the
internal rate of return and vesting of interests within JPM BHCA.
